Dermatological Conditions

Chronic Spontaneous Urticaria (CSU) is defined as the spontaneous occurrence of itchy wheals (hives), swelling of the skin, or both lasting for at least 6 weeks. This study is testing a new treatment for CSU called ligelizumab. The purpose of this study is to evaluate the safety and effectiveness of ligelizumab in treating patients with chronic spontaneous urticaria.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Hidradenitis suppurativa is an inflammatory skin disease that affects gland-bearing skin in the axillae (armpit), in the groin and under the breasts. It is characterised by recurrent boil-like nodules and abscesses that end up in pus-like discharge, difficult-to-heal open wounds (sinuses) and scarring.

This study is testing a new treatment for moderate to severe hidradenitis suppurativa. The new treatment is an investigational drug called Risankizumab.

The purpose of this study is to assess the safety and efficacy of two different doses of Risankizumab compared to placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa. After week 16 of the trial all participants will receive the study drug at the same dose for the remainder of the trial. The study drug is not currently approved for use in Australia. The total length of this trial is up to 85 weeks. Both Risankizumab and the placebo are administered by an injection.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Alopecia areata (AA) is an autoimmune disease, meaning a person’s immune system mistakenly attacks their own body. Alopecia areata is characterised by hair loss in single or multiple areas of the scalp, face or body.

This research study is testing the effects of a study drug for patients with alopecia areata. This study will explore whether the study drug is safe and can help patients with alopecia areata regrow hair. The duration of the study is 26 months (just over 2 years). All participants in this study will receive the active study drug. The study drug is not currently approved for use in Australia.

Alopecia areata (AA) is an autoimmune disease, meaning a person’s immune system mistakenly attacks their own body. Alopecia areata is characterised by hair loss in single or multiple areas of the scalp, face or body.

This research study is testing the effects of a study drug for patients with alopecia areata. This study will explore whether the study drug is safe and can help patients with alopecia areata regrow hair. The duration of the study is 26 months (just over 2 years). All participants in this study will receive the active study drug. The study drug is not currently approved for use in Australia.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Atopic dermatitis, often known as eczema, is a chronic, inflammatory skin disorder characterized by flaky skin lesions, intense itch, and a general deterioration in quality of life.

This research study is evaluating a new study drug called Lebrikizumab verses placebo. Both Lebrikizumab and the placebo are given every 2 weeks regularly as an injection under the skin, in patients with moderate to severe atopic dermatitis.

The purpose of this study is to assess the safety and efficacy of Lebrikizumab compared to placebo. The study drug is not currently approved for use in Australia. The duration of the study is 52 weeks.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Atopic dermatitis, often known as eczema, is a chronic, inflammatory skin disorder characterized by flaky skin lesions, intense itch, and a general deterioration in quality of life.

This research study is evaluating a new study drug called Nemolizumab, given regularly as an injection under the skin, in patients with moderate to severe atopic dermatitis not adequately controlled with topic corticosteroids. The purpose of this study is to assess the safety and efficacy of Nemolizumab compared to placebo.

The study drug is not currently approved for use in Australia. The duration of the study is 48 weeks with the opportunity to enrol in the long term extension study.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Atopic dermatitis, often known as eczema, is a chronic, inflammatory skin disorder characterized by flaky skin lesions, intense itch, and a general deterioration in quality of life. Eczema flares occur at variable and unpredictable intervals.

This research study is evaluating crisabarole ointment 2%, a steroid free topical ointment, as a long term maintenance treatment for eczema, as well as for reducing eczema flare ups, in those with mild to moderate eczema.

The duration of the study is 15 months. The study drug is not currently available on the PBS.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Atopic dermatitis, often known as eczema, is a chronic, inflammatory skin disorder characterized by flaky skin lesions, intense itch, and a general deterioration in quality of life. Eczema flares occur at variable and unpredictable intervals.

This research study is evaluating two drugs, Abrocitinib compared to Dupilumab in patients with moderate to severe atopic dermatitis on background topical corticosteroid therapy. Abrocitinib is a tablet, whilst dupilumab is given as an injection under the skin.

The duration of the study is 30 weeks with the option to enter a long term extension study following completion. The study drug is not currently available on the PBS.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Bullous pemphigoid (BP) is a rare, autoimmune skin condition characterised by blistering and itch. Many patients who have BP require treatment with topical steroids whilst others may require tablets, injections or infusions.

The investigational drug is dupilumab and is administered by injection.

The purpose of this research project is to measure how safe and effective dupilumab is in treating participants with BP who are off oral corticosteroids. Prior research studies in humans have shown that dupilumab may help control the immune system that is responsible for the signs and symptoms of BP and help achieve disease improvement.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4